Targeting the FGF23-Klotho endocrine axes might have therapeutic benefit for diseases of kidney in clinics.36 Whether blocking of FGF23 activities in patients with end-stage renal disease is an effective therapy to improve symptoms needs to be further studied. The gene discussed is FGF23; the disease is stage 5 chronic kidney disease.